Matches in Wikidata for { <http://www.wikidata.org/entity/Q58414263> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q58414263 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q58414263 description "im Juni 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58414263 description "scientific article published on 08 June 2018" @default.
- Q58414263 description "wetenschappelijk artikel" @default.
- Q58414263 description "наукова стаття, опублікована в червні 2018" @default.
- Q58414263 name "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 name "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 type Item @default.
- Q58414263 label "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 label "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 prefLabel "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 prefLabel "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 P1433 Q58414263-9462861A-C776-45B1-9200-2223F8EBCA46 @default.
- Q58414263 P1476 Q58414263-27C25DE7-DEF9-4C5D-ABE7-18F0216EB71D @default.
- Q58414263 P2093 Q58414263-41779F89-B768-4C9B-B688-82BF687C328A @default.
- Q58414263 P2093 Q58414263-74E2A7E1-1325-41F9-8C40-F5CC33057CDD @default.
- Q58414263 P2093 Q58414263-837E774A-6709-4CFE-9FB8-C0E5AC9764D1 @default.
- Q58414263 P2093 Q58414263-91E04BA7-B9E7-42E2-BF69-7D690F0EB145 @default.
- Q58414263 P2093 Q58414263-966697BA-FC08-4CB0-9F0F-55A7F503081D @default.
- Q58414263 P2093 Q58414263-9DB7F351-3BFB-4B45-8C43-2FABC4AFB641 @default.
- Q58414263 P2093 Q58414263-A0E5FC97-256A-4AB1-9F0B-4CE7AF69FB87 @default.
- Q58414263 P2093 Q58414263-AD442996-346F-4064-AE11-DD9F30A73E8A @default.
- Q58414263 P2093 Q58414263-C0DA387F-CF44-40BF-B166-51A57E0F0E95 @default.
- Q58414263 P304 Q58414263-FD47B6EE-EDD0-4EAC-92AB-572AB055FBF8 @default.
- Q58414263 P31 Q58414263-9C35D27E-332E-453F-8805-E5BBF34915A7 @default.
- Q58414263 P356 Q58414263-D861F1BC-D204-4095-BD30-9B159918CDB3 @default.
- Q58414263 P407 Q58414263-343D0926-1279-4B03-88CC-A3A4A5B9BE03 @default.
- Q58414263 P433 Q58414263-74321090-CB46-43EF-9C09-D308921307B3 @default.
- Q58414263 P478 Q58414263-89415892-98AE-465D-BC5D-46B9FEFB04A5 @default.
- Q58414263 P50 Q58414263-280CA2BD-75C2-4674-93A1-EE8920932C8C @default.
- Q58414263 P50 Q58414263-763CFC1A-8582-4FBF-AA5F-99243B775236 @default.
- Q58414263 P50 Q58414263-7902B6E7-84E6-430A-A171-B4CE1088EFC6 @default.
- Q58414263 P50 Q58414263-BD0AD8E5-A256-4CE6-A0AA-97F2B982E84E @default.
- Q58414263 P577 Q58414263-F07F5C6E-EDB8-4699-B87C-1DE1AA911547 @default.
- Q58414263 P698 Q58414263-309A1782-649F-4357-9F9F-14A690130E66 @default.
- Q58414263 P921 Q58414263-7A60BFB8-ECED-44C1-B4D6-E2D3A029A09B @default.
- Q58414263 P921 Q58414263-F1C7B6CF-6AD6-4DE8-AB54-4396201E1A6E @default.
- Q58414263 P921 Q58414263-F6204FEE-5007-4416-BFEA-BA5B754E5310 @default.
- Q58414263 P356 BJH.15204 @default.
- Q58414263 P698 29882583 @default.
- Q58414263 P1433 Q4970200 @default.
- Q58414263 P1476 "Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia" @default.
- Q58414263 P2093 "Alwin Krämer" @default.
- Q58414263 P2093 "Dan Liu" @default.
- Q58414263 P2093 "Florian Voss" @default.
- Q58414263 P2093 "Gesine Bug" @default.
- Q58414263 P2093 "Michael Lübbert" @default.
- Q58414263 P2093 "Pilar Garin-Chesa" @default.
- Q58414263 P2093 "Richard F Schlenk" @default.
- Q58414263 P2093 "Tillmann Taube" @default.
- Q58414263 P2093 "Utz Krug" @default.
- Q58414263 P304 "1018-1021" @default.
- Q58414263 P31 Q13442814 @default.
- Q58414263 P356 "10.1111/BJH.15204" @default.
- Q58414263 P407 Q1860 @default.
- Q58414263 P433 "6" @default.
- Q58414263 P478 "184" @default.
- Q58414263 P50 Q23564829 @default.
- Q58414263 P50 Q39749891 @default.
- Q58414263 P50 Q66385451 @default.
- Q58414263 P50 Q92866574 @default.
- Q58414263 P577 "2018-06-08T00:00:00Z" @default.
- Q58414263 P698 "29882583" @default.
- Q58414263 P921 Q180983 @default.
- Q58414263 P921 Q29496 @default.
- Q58414263 P921 Q5452194 @default.